Jazz Pharmaceuticals' Ziihera plus chemotherapy cuts death risk 24% in Phase 3 gastroesophageal cancer trial

By Public Technologies
  • Jazz Pharmaceuticals presented updated Phase 3 Ziihera survival results in first-line HER2-positive advanced gastroesophageal adenocarcinoma at ESMO 2026.
  • Ziihera with chemotherapy significantly improved overall survival versus trastuzumab with chemotherapy.
  • Adding tislelizumab sustained survival benefits versus trastuzumab with chemotherapy, but did not significantly improve survival over Ziihera with chemotherapy.
  • Safety profiles remained unchanged with longer follow-up.
  • The FDA cleared both Ziihera regimens on August 25, 2026, for first-line treatment in specified HER2-positive patient groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231015PR_NEWS_USPR_____SF78826) on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.